Literature DB >> 30391995

Moderators for depressed mood and systemic and transcriptional inflammatory responses: a randomized controlled trial of endotoxin.

Michael R Irwin1,2, Steve Cole3, Richard Olmstead3, Elizabeth C Breen3, Joshua Jin Cho3, Mona Moieni3,4, Naomi I Eisenberger4.   

Abstract

Activation of the innate immune system is thought to contribute to depression. Multiple social and behavioral factors are also known to instigate depression. Whether these socio-behavioral factors interact with inflammatory stimuli to alter proinflammatory responses and depressed mood is not known. In 115 healthy adults, social, emotional, and behavioral factors were assessed at baseline. A single infusion of endotoxin (Escherichia coli; 0.8 ng/kg of body weight) or placebo (0.9% saline) was administered with hourly assessment of depressed mood and proinflammatory cytokines (interleukin-6 (IL-6); tumor necrosis factor-α (TNF)). Inflammatory gene expression was examined at 30 min after infusion, prior to increase of inflammatory cytokines. As compared to placebo, endotoxin-induced increases of depressed mood were moderated by baseline levels of perceived stress, trait sensitivity to social disconnection, and severity of symptoms of anxiety and depression (all Ps < 0.05) but not early life stress, social status, social support, neuroticism, or sleep disturbance. Anxiety symptoms remained significant in multivariable analyses (P < 0.01). None of these socio-behavioral factors were related to increases in proinflammatory cytokines. Transcriptome profiling analyses indicated that perceived stress, sensitivity to social disconnection, and depressive symptoms were associated with increased activation of pro-inflammatory transcription control pathways (i.e., activator protein-1, nuclear factor-κB) in response to endotoxin (all Ps < 0.05). These results indicate that an array of socio-behavioral factors, which are associated with depression risk, modify vulnerability to inflammation-induced depressed mood. Together, these observations may be used to help target therapeutic interventions to mitigate occurrence of the inflammatory biotype of depression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30391995      PMCID: PMC6333799          DOI: 10.1038/s41386-018-0259-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  51 in total

1.  Computational identification of gene-social environment interaction at the human IL6 locus.

Authors:  Steven W Cole; Jesusa M G Arevalo; Rie Takahashi; Erica K Sloan; Susan K Lutgendorf; Anil K Sood; John F Sheridan; Teresa E Seeman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

2.  Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism.

Authors:  Francis E Lotrich; Robert E Ferrell; Mordechai Rabinovitz; Bruce G Pollock
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 3.  A critical review of human endotoxin administration as an experimental paradigm of depression.

Authors:  Nicole DellaGioia; Jonas Hannestad
Journal:  Neurosci Biobehav Rev       Date:  2009-08-08       Impact factor: 8.989

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward.

Authors:  Naomi I Eisenberger; Elliot T Berkman; Tristen K Inagaki; Lian T Rameson; Nehjla M Mashal; Michael R Irwin
Journal:  Biol Psychiatry       Date:  2010-08-16       Impact factor: 13.382

6.  An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences.

Authors:  Naomi I Eisenberger; Tristen K Inagaki; Lian T Rameson; Nehjla M Mashal; Michael R Irwin
Journal:  Neuroimage       Date:  2009-04-17       Impact factor: 6.556

Review 7.  Endotoxin-induced experimental systemic inflammation in humans: a model to disentangle immune-to-brain communication.

Authors:  Manfred Schedlowski; Harald Engler; Jan-Sebastian Grigoleit
Journal:  Brain Behav Immun       Date:  2013-10-24       Impact factor: 7.217

Review 8.  Depressive disorders and immunity: 20 years of progress and discovery.

Authors:  Michael R Irwin; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2007-03-13       Impact factor: 7.217

9.  A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes.

Authors:  Roos C Padmos; Manon H J Hillegers; Esther M Knijff; Ronald Vonk; Anne Bouvy; Frank J T Staal; Dick de Ridder; Ralph W Kupka; Willem A Nolen; Hemmo A Drexhage
Journal:  Arch Gen Psychiatry       Date:  2008-04

10.  A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

Authors:  Charles L Raison; Robin E Rutherford; Bobbi J Woolwine; Chen Shuo; Pamela Schettler; Daniel F Drake; Ebrahim Haroon; Andrew H Miller
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

View more
  13 in total

1.  Inflammation and Risk of Depression in HIV: Prospective Findings From the Multicenter AIDS Cohort Study.

Authors:  Haidong Lu; Pamela J Surkan; Michael R Irwin; Glenn J Treisman; Elizabeth C Breen; Ned Sacktor; Ron Stall; Steven M Wolinsky; Lisa P Jacobson; Alison G Abraham
Journal:  Am J Epidemiol       Date:  2019-11-01       Impact factor: 4.897

2.  Kynurenine metabolism and inflammation-induced depressed mood: A human experimental study.

Authors:  Jennifer L Kruse; Joshua Hyong-Jin Cho; Richard Olmstead; Lin Hwang; Kym Faull; Naomi I Eisenberger; Michael R Irwin
Journal:  Psychoneuroendocrinology       Date:  2019-07-03       Impact factor: 4.905

3.  Inflammation and depression in young people: a systematic review and proposed inflammatory pathways.

Authors:  Yara J Toenders; Liliana Laskaris; Christopher G Davey; Michael Berk; Yuri Milaneschi; Femke Lamers; Brenda W J H Penninx; Lianne Schmaal
Journal:  Mol Psychiatry       Date:  2021-10-11       Impact factor: 15.992

4.  Psychosocial Resilience to Inflammation-Associated Depression: A Prospective Study of Breast-Cancer Survivors.

Authors:  Andrew W Manigault; Kate R Kuhlman; Michael R Irwin; Steve W Cole; Patricia A Ganz; Catherine M Crespi; Julienne E Bower
Journal:  Psychol Sci       Date:  2022-08-05

Review 5.  Biobehavioral Implications of Covid-19 for Transplantation and Cellular Therapy Recipients.

Authors:  Jennifer M Knight; Mallory R Taylor; Kelly E Rentscher; Elisabeth C Henley; Hannah A Uttley; Ashley M Nelson; Lucie M Turcotte; Natalie S McAndrew; Hermioni L Amonoo; Lathika Mohanraj; Debra Lynch Kelly; Erin S Costanzo
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

6.  Transcriptomic predictors of inflammation-induced depressed mood.

Authors:  Joshua Hyong-Jin Cho; Michael R Irwin; Naomi I Eisenberger; Donald M Lamkin; Steve W Cole
Journal:  Neuropsychopharmacology       Date:  2019-01-14       Impact factor: 7.853

Review 7.  Toll-Like Receptor Signaling in Depression.

Authors:  Leandra K Figueroa-Hall; Martin P Paulus; Jonathan Savitz
Journal:  Psychoneuroendocrinology       Date:  2020-09-01       Impact factor: 4.905

8.  Vulnerability to inflammation-related depressive symptoms: Moderation by stress in women with breast cancer.

Authors:  Andrew W Manigault; Kate R Kuhlman; Michael R Irwin; Steve W Cole; Patricia A Ganz; Catherine M Crespi; Julienne E Bower
Journal:  Brain Behav Immun       Date:  2021-03-09       Impact factor: 7.217

9.  Sex Differences in the Effect of Inflammation on Subjective Social Status: A Randomized Controlled Trial of Endotoxin in Healthy Young Adults.

Authors:  Mona Moieni; Keely A Muscatell; Ivana Jevtic; Elizabeth C Breen; Michael R Irwin; Naomi I Eisenberger
Journal:  Front Psychol       Date:  2019-10-01

10.  Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial.

Authors:  Vincent Millischer; Matthias Heinzl; Anthi Faka; Michael Resl; Ada Trepci; Carmen Klammer; Margot Egger; Benjamin Dieplinger; Martin Clodi; Lilly Schwieler
Journal:  J Neuroinflammation       Date:  2021-07-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.